The DOI matches its Crossref record.
High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer.
Abstract
PURPOSE: This review was undertaken to examine the evidence of effectiveness of high-dose chemotherapy and autologous bone marrow transplantation (HDC/ABMT) for the treatment of metastatic breast cancer and to compare the magnitudes of the benefits and harms of HDC/ABMT with those of conventional doses of chemotherapy. DESIGN: Published studies were reviewed and analyzed. RESULTS: No randomized controlled trials have been published that evaluate HDC/ABMT. Only one internally controlled study has been conducted; it demonstrated that HDC/ABMT and conventional treatment have virtually identical outcomes. Comparisons of uncontrolled clinical series are confounded by patient selection and other biases. Gross comparisons indicate that, compared with conventional-dose chemotherapy, HDC/ABMT achieves (1) higher complete response rates (36% v 8%), (2) higher overall response rates (70% v 39%), (3) similar median response durations (8 months v 9.6 months), (4) similar median survival durations (16 months v 16.6 months), and (5) similar overall survival rates (eg, 43% 2-year survival v 39%). Observations of cases with longer-term disease-free survival are promising but not conclusive. High-dose chemotherapy with ABMT has a higher treatment-related mortality rate (5% to 15% v 1%), a high rate of nonmortal toxicity (approximately 30%), and a high rate of side effects (approaching 100%). CONCLUSIONS: Firm conclusions are not possible because of the lack of controlled studies and the presence of numerous biases. However, the existing evidence does not demonstrate that HDC/ABMT is superior to conventional-dose chemotherapy for the treatment of metastatic breast cancer. Randomized controlled trials are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301802 · Cited by 961
Hortobagyi, G. N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810013391407 · Cited by 781
van Dam, F. S. A. M., Boogerd, W., Schagen, S. B., Muller, M. J., Droogleever Fortuyn, M. E., Wall, E. V. D., & Rodenhuis, S. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.3.210 · Cited by 763
Helena Michelson, C. B. (2000) · Acta Oncologica · doi:10.1080/028418600750013384 · Cited by 379
Vinorelbine and Paclitaxel as First-Line Chemotherapy in Metastatic Breast Cancer
Acuña, L. R., Langhi, M., Pérez, J., Acuña, J. R., Machiavelli, M., Lacava, J., Vallejo, C., Romero, A., Fasce, H., Ortiz, E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.74 · Cited by 54
Metadata
- Authors
- Eddy, D. M.
- Venue
- Journal of Clinical Oncology
- Published
- 1992-04
- Volume
- 10
- Issue
- 4
- Pages
- 657-670
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2113143479
- Cited by
- 174
- References
- 0
- FWCI
- 12.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. https://app.cochat.ai/papers/10.1200/jco.1992.10.4.657
- The paper
- Eddy, D. M. (1992). High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1992.10.4.657
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.